In the News

1855 News Items found
MSK urologic surgeon and prostate cancer specialist Jonathan Fainberg
Q&A
Prostate cancer expert Jonathan Fainberg, MD, discusses the risk of complications from prostate cancer surgery and explains why not all procedures are alike.
A researcher working in an MSK lab
MSK Research Highlights, December 16, 2025
New MSK research finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will turn into multiple myeloma; develops a data-driven approach that could catch lymphedema earlier; and shows that nurse-led palliative care delivered by phone could serve as a scalable model.
microscope image of regulatory T cells
A new MSK study finds that in colorectal cancer, not all regulatory T cells are created equal. One subtype suppresses cancer growth while another aids it. The findings could help improve immunotherapy treatment for the majority of patients with colorectal cancer, and potentially for other cancers.
MSK patient Ellen Coopersmith smiling in a rowboat in Central Park
Learn about the clinical trials and research at MSK that led to FDA approvals in 2025, expanding treatment options for a range of different cancers.
Binglong Zhang at work in the lab
MSK researchers continued to make strides against cancer in 2025. Learn about some of their top discoveries.
A women sitting in a chair holding a bell
Learn about some of the most important advances in cancer treatment at MSK in 2025.
A close-up of fingers inserting acupuncture needles into skin
In the Clinic
A phase 2 randomized clinical trial at MSK has found that acupuncture can improve cognitive abilities in breast cancer survivors experiencing "brain fog."
MSK hematologist-oncologist Dr. Lia Palomba
Article
Read about a new CAR T cell therapy now approved for marginal zone lymphoma (MZL).
MSK medical oncologist Komal Jhaveri.
Article
Read about a new treatment for people with some ER+, HER2- advanced breast cancers.
MSK medical oncologist and bladder cancer specialist Jonathan Rosenberg
A powerful therapy called an antibody-drug conjugate has been approved by the FDA for more people with bladder cancer.